Long-term follow up of AHC Ito T. et al. She was referred to our hospital for further evaluation at 6 years of age.
Laboratory testing and imaging by head computed tomography (CT), single photoemission CT (SPECT), and interictal EEG showed no abnormal findings. We diagnosed this patient with AHC after applying the diagnostic criteria, including the presence of repetitive hemiplegia, hemiparesis after hemiplegia, and developmental delay when she was 6-year-old [7] .
She initially presented with focal motor seizure, which evolved to Flunarizine was also effective for the epileptic seizures, and 1 year after re-starting the drug administration she had showed only two episodes of status seizure.
【Discussion】
In contract to patients with the higher frequency p.E815K or p.D801N mutation, there is limited information about the phenotype of AHC cases with other minor genotypes. In this study, we reviewed the clinical course of a female AHC patient with p.G755S mutation and compared our findings with previous clinical reports of the same mutation (6 patients, Table 1 ). One adult and two pediatric cases among the six patients were evaluated as mild AHC because there were no further episodes of clinical decline [3] . However, the long-term outcome of these patients is unclear due to the limited follow-up period. To the best of knowledge, we report herein the oldest patient with AHC and a G755S mutation. Our case showing recurrent status epilepticus and sudden deterioration after 35 years of age suggests that the long-term outcome of this minor genotype could be poor even though the effects are moderate at a younger age. This insight is supported by case 1 in Long-term follow up of AHC Ito T. et al. Table 1 , who showed rapid deterioration after epileptic status at the age of 12 years [4] . We think the possibility of her deterioration due to not only seizure status but also natural course of this disease. Especially, case 1 and our patient would have seizure status and deterioration after quitting flunarizine. These results might imply that these mutations presented a particular benefit on flunarizine treatment, although it should be confirmed in future additional study.
Clinicians should therefore be aware of the potential for aggravated symptoms during adolescence or adulthood, especially in patients with E815K and G755A/S mutations, as Sasaki et al mentioned [4] . Previous reports also indicated that flunarizine in AHC patients prevents paralysis and regression [8] , and our case confirms the effectiveness of flunarizine in patients with AHC. In other genotypes of AHC reviewed, some patients regressed after stopping flunarizine [4] . Of note in the current case, the stability of symptoms during the initial 10-year administration of flunarizine suggests that this compound could have preventive effect for neuronal degradation in AHC, although more cases are necessary for meaningful analysis of this proposal.
Long-term follow up of AHC Ito T. et al. Table 1 . AHC with p.Gly755Ser (p.G755S) mutation in ATP1A3 gene in previous reports and our case.
